Cellectar Biosciences develops proprietary oncology drugs built around its Phospholipid Drug Conjugate™ (PDC) delivery platform. News about CLRB commonly centers on targeted radiotherapeutic programs, including iopofosine I 131 for Waldenström macroglobulinemia and CLR 121125, also called CLR 125, an iodine-125 Auger-emitting program for solid tumors such as triple negative breast, lung and colorectal cancers.
Company updates also cover clinical data from the CLOVER WaM study, oncology conference presentations, European and U.S. regulatory interactions, intellectual property protection, securities financings, and periodic financial results with corporate updates. The recurring disclosures reflect a late-stage clinical biopharmaceutical company funding and advancing cancer-cell-targeting treatments through internal development and research collaborations.
Cellectar Biosciences (NASDAQ: CLRB) reported a wider third-quarter net loss while advancing iopofosine I 131 toward a planned accelerated-approval application. Net loss was $7,974,743, versus $4,443,877 a year earlier; loss per share narrowed to $0.46 from $1.41. Cash totaled $24,582,115 at September 30, 2026, versus $13,196,033 at year-end 2025, following approximately $31.7 million in net offering proceeds.
The company expects cash to fund budgeted operations into Q2 2027, first dosing in its confirmatory Phase 3 trial in Q1 2027, and an accelerated-approval application in 1H 2027. A Phase 2b subset of 24 evaluable patients with Waldenström macroglobulinemia treated immediately after BTK inhibitor therapy showed an 87.5% overall response rate and 16.0-month median response duration. CLR 125 enrollment continues, with initial dosimetry and safety data expected in Q4 2026.
Cellectar Biosciences (NASDAQ: CLRB) will present updated iopofosine I 131 clinical analyses and its Phase 3 study design at the ASH annual meeting. The three posters cover Waldenström macroglobulinemia, a blood cancer, and will be presented December 12 and 14, 2026, in New Orleans. Updated 12-month follow-up from the Phase 2b CLOVER WaM trial showed durable responses in heavily pretreated patients. Patients treated after only two prior lines of therapy had longer responses than more heavily pretreated patients.
The Phase 3 confirmatory study will compare iopofosine I 131 with rituximab-cyclophosphamide-dexamethasone in patients previously treated with a Bruton tyrosine kinase inhibitor. Site activation and start-up activities are underway. Cellectar anticipates first patient dosing in the first quarter of 2027 and targets an FDA submission seeking accelerated approval in the first half of 2027.
Cellectar Biosciences (CLRB) will report third-quarter financial results and provide a corporate update on November 10, 2026.
The quarter ended September 30, 2026. The conference call and webcast will begin at 8:30 a.m. Eastern Time, with a replay available in the Events section of the company’s Investor Relations website.
Cellectar Biosciences (CLRB) reported a complete response lasting more than eight years in one heavily pretreated lymphoma patient given iopofosine I 131. The patient had diffuse large B-cell lymphoma (DLBCL), four prior treatment lines and a stem cell transplant. After a single dose, she achieved complete response by Day 85; as of May 2026, she had no disease progression and needed no additional anticancer therapy. Blood-related toxicities resolved.
Cellectar expects patient dosing in its confirmatory Phase 3 Waldenström macroglobulinemia study to begin in the first quarter of 2027 and plans an FDA accelerated approval application in the first half of 2027.
Cellectar Biosciences (CLRB) presented Phase 2b subgroup results for iopofosine I 131 in patients with Waldenström macroglobulinemia treated immediately after BTK inhibitors.
The analysis included 24 patients from the CLOVER WaM trial’s previously reported 12-month follow-up dataset. Overall response was 87.5%, major response was 79.2% and clinical benefit was 100%. Median response duration was 16.0 months; treatment-free survival was 19.1 months. Treatment-emergent adverse events occurred in less than 10% of patients; the only Grade 3 or higher events were cytopenias, or low blood cell counts.
Cellectar expects first patient dosing in its confirmatory randomized Phase 3 trial in 1Q27, with progression-free survival as the expected primary endpoint. The company anticipates submitting an application for U.S. accelerated approval in 1H27.
Cellectar Biosciences (CLRB) reported a 79.2% major response rate in a Phase 2 CLOVER-WaM subgroup treated with iopofosine I 131. The analysis covered patients with Waldenström macroglobulinemia who received the treatment immediately after BTK inhibitor therapy and had received at least two prior treatment lines. The overall response rate was 87.5%, and duration of response exceeded 16 months. The data are scheduled for presentation on October 15, 2026.
Cellectar plans to dose patients in a confirmatory Phase 3 trial in early 2027 and file a U.S. accelerated-approval application in the first half of 2027. The treatment has Breakthrough Therapy Designation. Cellectar expects a six-month review and sees potential approval by the end of 2027.
Cellectar Biosciences (NASDAQ: CLRB) reported second quarter 2026 results and advanced its radiotherapeutic pipeline. For relapsed/refractory Waldenström macroglobulinemia, updated Phase 2b CLOVER WaM data in patients treated immediately after BTK inhibitors showed a 100% clinical benefit rate, 87.5% overall response rate and 79.2% major response rate, with median duration of response of 16 months and 20% of patients exceeding 30 months.
The company initiated site activation for a randomized Phase 3 confirmatory iopofosine I 131 trial, with first dosing expected in early 2027 and a planned mid‑2027 NDA submission under FDA’s Accelerated Approval Program. CLR 125 entered Phase 1b in triple‑negative breast cancer, and Phase 1 multiple myeloma data for iopofosine I 131 were published. Cellectar closed a May 2026 financing providing approximately $35 million upfront, lifting cash to $34.0 million at June 30, 2026, which is expected to fund operations into Q2 2027. Quarterly R&D rose to $4.6 million, G&A declined to $2.6 million, and net loss was $6.9 million, or $0.57 per share.
Cellectar Biosciences (NASDAQ: CLRB) will report its second quarter 2026 financial results and provide a corporate update on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time. The event will include a conference call and webcast, with a replay available on the company’s Investor Relations Events page.
Cellectar Biosciences (NASDAQ: CLRB) reported publication of a Phase 1 dose-escalation study of iopofosine I 131 plus low-dose dexamethasone in 31 heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers.
Among 26 efficacy-evaluable patients, 84.6% achieved stable disease or better. The overall response rate (ORR) was 15.4%, including four partial responses, and a subgroup of evaluable patients (n=10) receiving at least 60 mCi showed a 30% ORR. Investigators described a favorable, manageable safety profile, with adverse events mainly predictable, reversible hematologic toxicities and generally low-grade non-hematologic events, and no new safety signals. According to Cellectar, these findings support continued development of iopofosine I 131 as a novel targeted radiotherapeutic across multiple B‑cell malignancies and suggest potential for repeat dosing strategies.
Cellectar Biosciences (NASDAQ: CLRB) reported new Phase 2b CLOVER WaM data for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia patients treated immediately after BTK inhibitor therapy (n=24). Outcomes included 100% clinical benefit, 87.5% overall response, 79.2% major response, and median duration of response of 16 months, with 20% exceeding 30 months.
The treatment showed a manageable safety profile, with cytopenias as the only Grade ≥3 adverse event. Based on these results, Cellectar plans to pursue U.S. accelerated approval and initiate a Phase 3 confirmatory trial in 4Q26.